120 related articles for article (PubMed ID: 25831789)
1. [Heart failure].
Ozaki Y; Koganemaru S; Suyama K; Miura Y; Takano T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():389-98. PubMed ID: 25831789
[No Abstract] [Full Text] [Related]
2. Trastuzumab cardiac side effects: only time will tell.
Levine MN
J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
[No Abstract] [Full Text] [Related]
3. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity associated with trastuzumab and chemotherapy used for HER2-positive cancers.
Mardis C
MLO Med Lab Obs; 2014 Apr; 46(4):18, 20. PubMed ID: 24783682
[No Abstract] [Full Text] [Related]
5. Cardiac testing to manage cardiovascular risk in cancer patients.
Davis M; Witteles RM
Semin Oncol; 2013 Apr; 40(2):147-55. PubMed ID: 23540740
[TBL] [Abstract][Full Text] [Related]
6. Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab.
Martins SJ; Modesto Dos Santos V; Thommen Teles L; Alves Leite V
Rev Med Chil; 2012 Jun; 140(6):763-6. PubMed ID: 23282614
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-related cardiotoxicity.
Aggarwal S; Kamboj J; Arora R
Ther Adv Cardiovasc Dis; 2013 Apr; 7(2):87-98. PubMed ID: 23487044
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
10. Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Witteles RM; Fowler MB; Telli ML
Heart Fail Clin; 2011 Jul; 7(3):333-44. PubMed ID: 21749885
[TBL] [Abstract][Full Text] [Related]
11. Management of trastuzumab-related cardiac dysfunction.
Carver JR
Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of trastuzumab in clinical practice.
McArthur HL; Chia S
N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
[No Abstract] [Full Text] [Related]
13. Breast cancer drug warning.
Johns Hopkins Med Lett Health After 50; 2012 Dec; 24(11):8. PubMed ID: 23342677
[No Abstract] [Full Text] [Related]
14. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e1-e2. PubMed ID: 27755236
[No Abstract] [Full Text] [Related]
15. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice.
Goel S; Beith JM
J Clin Oncol; 2011 Mar; 29(7):e175-6. PubMed ID: 21189375
[No Abstract] [Full Text] [Related]
16. [Heart failure in women treated with adjuvant trastuzumab for breast cancer].
Tarantini L; Feola M; Albini A; Gori S; Foglietta J; Cicoira MA; Pulignano G
G Ital Cardiol (Rome); 2012 May; 13(5 Suppl 1):54S-62S. PubMed ID: 23678535
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-induced cardiomyopathy.
Guglin M; Cutro R; Mishkin JD
J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
[TBL] [Abstract][Full Text] [Related]
18. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab cardiotoxicity in patients with breast cancer.
Freitas AF; Rassi S
Arq Bras Cardiol; 2014 Feb; 102(2):200. PubMed ID: 24676377
[No Abstract] [Full Text] [Related]
20. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.
Lemieux J; Diorio C; Côté MA; Provencher L; Barabé F; Jacob S; St-Pierre C; Demers E; Tremblay-Lemay R; Nadeau-Larochelle C; Michaud A; Laflamme C
Anticancer Res; 2013 Jun; 33(6):2569-76. PubMed ID: 23749910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
